Clinical, Radiological and Pathological Features of a Large American Cohort of Spinocerebellar Ataxia (SCA27B)
- Author(s)
- Abou Chaar, W; Eranki, AN; Stevens, HA; Watson, SL; Wong, DY; Avila, VS; Delfeld, M; Gary, AJ; Tawde, S; Triebold, M; Cherchi, M; Xie, T; Lockhart, PJ; Bahlo, M; Pellerin, D; Dicaire, MJ; Danzi, M; Zuchner, S; Brais, BC; Perlman, S; Burmeister, M; Paulson, H; Srinivasan, S; Schut, L; Bower, M; Bushara, K; Liao, C; Shakkottai, VG; Collins, J; Clark, HB; Das, S; Fogel, BL; Gomez, CM;
- Journal Title
- Annals of Neurology
- Publication Type
- Sep 12 epub ahead of print
- Abstract
- OBJECTIVES: Spinocerebellar ataxia 27B due to GAA repeat expansions in the fibroblast growth factor 14 (FGF14) gene has recently been recognized as a common cause of late-onset hereditary cerebellar ataxia. Here we present the first report of this disease in the US population, characterizing its clinical manifestations, disease progression, pathological abnormalities, and response to 4-aminopyridine in a cohort of 102 patients bearing GAA repeat expansions. METHODS: We compiled a series of patients with SCA27B, recruited from 5 academic centers across the United States. Clinical manifestations and patient demographics were collected retrospectively from clinical records in an unblinded approach using a standardized form. Post-mortem analysis was done on 4 brains of patients with genetically confirmed SCA27B. RESULTS: In our cohort of 102 patients with SCA27B, we found that SCA27B was a late-onset (57 ± 12.5 years) slowly progressive ataxia with an episodic component in 51% of patients. Balance and gait impairment were almost always present at disease onset. The principal finding on post-mortem examination of 4 brain specimens was loss of Purkinje neurons that was most severe in the vermis most particularly in the anterior vermis. Similar to European populations, a high percent of patients 21/28 (75%) reported a positive treatment response with 4-aminopyridine. INTERPRETATION: Our study further estimates prevalence and further expands the clinical, imaging and pathological features of SCA27B, while looking at treatment response, disease progression, and survival in patients with this disease. Testing for SCA27B should be considered in all undiagnosed ataxia patients, especially those with episodic onset. ANN NEUROL 2024.
- Publisher
- Wiley
- Research Division(s)
- Population Health And Immunity
- PubMed ID
- 39263992
- Publisher's Version
- https://doi.org/10.1002/ana.27060
- Open Access at Publisher's Site
https://doi.org/10.1002/ana.27060- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-10-04 10:44:39
Last Modified: 2024-10-04 10:51:24